Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Regeneron Pharmaceuticals Q2 2024 Adj EPS $11.56 Beats $10.61 Estimate, Sales $3.55B Beat $3.38B Estimate

Author: Benzinga Newsdesk | August 01, 2024 06:33am
Regeneron Pharmaceuticals (NASDAQ:REGN) reported quarterly earnings of $11.56 per share which beat the analyst consensus estimate of $10.61 by 8.95 percent. The company reported quarterly sales of $3.55 billion which beat the analyst consensus estimate of $3.38 billion by 4.97 percent. This is a 12.32 percent increase over sales of $3.16 billion the same period last year.

Posted In: REGN


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist